Floatz logo

Zeleciment Rostudirsen

Muscular Dystrophy

Dyne TherapeuticsUNKNOWNPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Muscular Dystrophy cohort.

Asset / SponsorPhaseRating
gsk2402968
GlaxoSmithKline
Phase 3BB
Ataluren
PTC Therapeutics
Phase 3B
Deramiocel
Capricor Inc.
Phase 3B
Tadalafil
University of Florida
Phase 2B
Enalapril
InCor Heart Institute
Phase 3B

View all 10 →

Same molecule, other indications

Zeleciment Rostudirsen is also rated in:

neuromuscular disease caused by qualitative or quantitative defects of dystrophinActive
B
Indicative · Phase 3
60 / 100
View asset →
developmental defect during embryogenesisActive
B
Indicative · Phase 3
60 / 100
View asset →
hereditary diseaseActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →